Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2006 pp 425–438Cite as

Antikoagulantien und Thrombozytenaggregationshemmer

  • Chapter

  • 427 Accesses

Auszug

Nach dem Rückgang der Verordnungen der Thrombozytenaggregationshemmer 2004 ist 2005 wieder ein Anstieg der Verordnungen um 12% zu verzeichnen, der dem langfristigen Trend folgt. Ursache für die Verordnungsabnahme der Acetylsalicylsäure im Jahr 2004 war der Ausschluß nicht verschreibungspflichtiger Arzneimittel aus der vertragsärztlichen Versorgung. Bei den Antikoagulantien sind die Verordnungen der Vitamin-K-Antagonisten (Phenprocoumon, Warfarin) sowie der niedermolekularen Heparine 2005 deutlich gestiegen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD 001342.

    Google Scholar 

  • Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.

    Article  Google Scholar 

  • Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR et al. (2006): Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717.

    Article  PubMed  CAS  Google Scholar 

  • Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH for the CLASSICS Investigators (2000): Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102: 624–629.

    PubMed  CAS  Google Scholar 

  • Born GVR, Collins R (1997): Aspirin versus clopidogrel: the wrong question? Lancet 349: 806–807.

    Article  PubMed  CAS  Google Scholar 

  • CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.

    Article  Google Scholar 

  • Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244.

    Article  PubMed  CAS  Google Scholar 

  • De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080.

    Article  PubMed  CAS  Google Scholar 

  • Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet 364: 331–337.

    Article  PubMed  CAS  Google Scholar 

  • Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13.

    Article  PubMed  CAS  Google Scholar 

  • Eikelboom JW, Anand SS, Maimberg K, Weitz JI, Ginsberg JS, Yusuf S (2000): Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355: 1936–1942.

    Article  PubMed  CAS  Google Scholar 

  • Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655.

    Article  CAS  Google Scholar 

  • Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.

    Article  Google Scholar 

  • Gorelick PB, Born GVR, d’Agostino RB, Hanley DF Jr, Moye L, Pepine CJ (1999): Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 30: 1716–1721.

    PubMed  CAS  Google Scholar 

  • Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Longterm incidence of recurrent venous thromboembolism. Am J Hematol 67: 10–14.

    Article  PubMed  CAS  Google Scholar 

  • Gum PA, Kottke-Marchant K, Poggio ED, et al. (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235.

    Article  PubMed  CAS  Google Scholar 

  • Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321: 501–507.

    Article  PubMed  CAS  Google Scholar 

  • Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003): Aspirin and clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med 163: 1145–1153.

    Article  PubMed  CAS  Google Scholar 

  • Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R (2004): Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess (38): iii–iv, 1–196.

    Google Scholar 

  • Keng TB (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 114: 394–396.

    Article  PubMed  CAS  Google Scholar 

  • Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334: 682–687.

    Article  PubMed  CAS  Google Scholar 

  • Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607.

    Article  PubMed  CAS  Google Scholar 

  • Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL et al. (1998): A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339: 1665–1671.

    Article  PubMed  CAS  Google Scholar 

  • Levine M, Gent M, Hirsh J, Leclerc J, Anderson D et al. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677–681.

    Article  PubMed  CAS  Google Scholar 

  • Martel N, Lee J, Wells PS (2005): Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710–2715.

    Article  PubMed  CAS  Google Scholar 

  • Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Katarajan MK et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533.

    Article  PubMed  CAS  Google Scholar 

  • Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930.

    Article  PubMed  CAS  Google Scholar 

  • The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345: 494–502.

    Article  Google Scholar 

  • The ESPRIT Study Group (2006): Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673.

    Article  CAS  Google Scholar 

  • Van der Heijden JF, Hutten BA, Büller HR, Prins MH (2002): Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Reviews). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.

    Google Scholar 

  • Walenga JM (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105: 401–405.

    Article  PubMed  CAS  Google Scholar 

  • White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20.

    Article  CAS  Google Scholar 

  • Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwig-Universität, Albertstraße 25, 79104, Freiburg

    Prof. Dr. med. Lutz Hein

  2. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Lutz Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Hein, L., Schwabe, U. (2007). Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation